Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Human mannose receptor (CD206) in immune response: novel insights into vaccination strategies using a humanized mouse model.

Dasgupta S, Bayry J, Lacroix-Desmazes S, Kaveri SV.

Expert Rev Clin Immunol. 2007 Sep;3(5):677-81. doi: 10.1586/1744666X.3.5.677.

PMID:
20477018
2.

Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged.

Tang YC, Thoman M, Linton PJ, Deisseroth A.

Cancer Immunol Immunother. 2009 Dec;58(12):1949-57. doi: 10.1007/s00262-009-0718-3. Epub 2009 May 15. Review.

PMID:
19444444
3.

Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine.

Zuckermann FA, Martin S, Husmann RJ, Brandt J.

Adv Vet Med. 1999;41:447-61. Review.

PMID:
9890035
4.

A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes.

Dasgupta S, Navarrete AM, Bayry J, Delignat S, Wootla B, André S, Christophe O, Nascimbeni M, Jacquemin M, Martinez-Pomares L, Geijtenbeek TB, Moris A, Saint-Remy JM, Kazatchkine MD, Kaveri SV, Lacroix-Desmazes S.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):8965-70. Epub 2007 May 14.

5.

DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response.

Whalen RG, Leclerc C, Dériaud E, Schirmbeck R, Reimann J, Davis HL.

Ann N Y Acad Sci. 1995 Nov 27;772:64-76. Review.

PMID:
8546414
6.
7.

[MHC tetramers: tracking specific immunity].

Kosor E, Gagro A, Drazenović V, Kuzman I, Jeren T, Rakusić S, Rabatić S, Markotić A, Gotovac K, Sabioncello A, Cecuk E, Kerhin-Brkljacić V, Gjenero-Margan I, Kaić B, Mlinarić-Galinović G, Kastelan A, Dekaris D.

Acta Med Croatica. 2003;57(4):255-9. Review. Croatian.

PMID:
14639858
8.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
9.

Mannose receptor-targeted vaccines.

Keler T, Ramakrishna V, Fanger MW.

Expert Opin Biol Ther. 2004 Dec;4(12):1953-62. Review.

PMID:
15571457
10.

[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.

PMID:
17240920
11.

Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.

Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, Takino H, Mori F, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R.

Cancer Immunol Immunother. 2009 Aug;58(8):1195-206. doi: 10.1007/s00262-008-0632-0. Epub 2008 Dec 2.

PMID:
19048251
12.

A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells.

Krueger P, Nitz C, Foster R, MacDonald C, Gelber O, Lalehzadeh G, Goodson R, Winter J, Gelber C.

Cancer Immunol Immunother. 2003 Jun;52(6):367-77. Epub 2003 Apr 1.

PMID:
12669243
14.

A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.

Conforti A, Peruzzi D, Giannetti P, Biondo A, Ciliberto G, La Monica N, Aurisicchio L.

J Immunother. 2009 Sep;32(7):744-54. doi: 10.1097/CJI.0b013e3181aee1b6.

PMID:
19561534
16.
17.

Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.

Ciesielski MJ, Kazim AL, Barth RF, Fenstermaker RA.

Cancer Immunol Immunother. 2005 Feb;54(2):107-19. Epub 2004 Aug 31.

PMID:
15340764
18.

Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.

Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Kim M, Weber CE, Baccala AA, Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF.

Cancer Chemother Pharmacol. 2000;46 Suppl:S67-72.

PMID:
10950151
19.
20.

Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.

Morera Y, Bequet-Romero M, Ayala M, Lamdán H, Agger EM, Andersen P, Gavilondo JV.

Angiogenesis. 2008;11(4):381-93. doi: 10.1007/s10456-008-9121-5. Epub 2008 Nov 26.

PMID:
19034678

Supplemental Content

Support Center